Want to see BNBX full AI Analyst Report?
BNBX Stock Chart & Stats
$1.48
--
Market closed
$1.48
--
Day’s Range― - ―
52-Week Range$0.32 - $7.15
Previous CloseN/A
VolumeN/A
Average Volume (3M)1.96M
Market Cap
$2.51M
Enterprise Value-$316.97K
Total Cash (Recent Filing)$949.09K
Total Debt (Recent Filing)$0.00
Price to Earnings (P/E)―
Beta2.32
Next Earnings
Aug 06, 2026EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-39.93
Shares Outstanding7,197,228
10 Day Avg. Volume46,292
30 Day Avg. Volume1,955,224
Financial Highlights & Ratios
PEG Ratio>-0.01
Price to Book (P/B)0.87
Price to Sales (P/S)0.94
P/FCF Ratio-0.16
Enterprise Value/Market Cap-0.13
Enterprise Value/Revenue-0.15
Enterprise Value/Gross Profit-0.35
Enterprise Value/Ebitda<0.01
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)-82.5
Revenue Forecast (FY)$7.40M
Bulls Say, Bears Say
Bulls Say
Low Leverage And Stronger Equity BaseVery low debt and a marked increase in equity provide durable financial flexibility over the next several months. This reduces bankruptcy and rollover risk, supports continuing operations while management pursues strategic options, and improves the company's ability to access financing without immediate distress.
Material Recent Revenue ReboundA nearly 200% TTM revenue rebound indicates that demand or monetization initiatives are working. If sustained, higher topline provides a platform to scale fixed costs and improve unit economics, enabling durable margin recovery if cost structure is aligned with the new revenue base.
Committed Preferred Financing To Bolster LiquidityThe private placement with $4.1M committed increases near-term liquidity and buys time for strategic actions, including monetization of the profitable LineaRx DNA unit. Structural backing from investors and guaranteed proceeds by subsidiaries strengthens the company's ability to execute multi-month value-creation plans.
Bears Say
Extreme Operating And Net LossesMargins are structurally weak: very low gross margin and extreme negative operating/net margins show costs far exceed revenue. Without meaningful structural cost reduction or sustained higher revenue, these losses will persist, undermining long-term value creation and financing capacity.
Deep Negative Operating And Free Cash FlowSustained negative operating and free cash flow (~-$13.8M TTM) is a durable constraint on the business. Persistent burn forces reliance on external financing, limits R&D and commercialization spend, and increases dilution or creditor risk if revenue and margins don't improve.
Preferred Financing Seniority And Dilution RiskThe preferred stock's seniority, liquidation preference and conversion terms structurally subordinate common equity and raise dilution risk. This governance and capital-structure change can limit common shareholders' upside and complicate future equity raises or M&A, affecting long-term returns.
BNB Plus News
BNBX FAQ
What was BNB Plus’s price range in the past 12 months?
BNB Plus lowest stock price was $0.32 and its highest was $7.15 in the past 12 months.
What is BNB Plus’s market cap?
BNB Plus’s market cap is $2.51M.
When is BNB Plus’s upcoming earnings report date?
BNB Plus’s upcoming earnings report date is Aug 06, 2026 which is in 26 days.
How were BNB Plus’s earnings last quarter?
BNB Plus released its earnings results on May 07, 2026. The company reported -$0.685 earnings per share for the quarter, missing the consensus estimate of N/A by -$0.685.
Is BNB Plus overvalued?
According to Wall Street analysts BNB Plus’s price is currently Overvalued.
Does BNB Plus pay dividends?
BNB Plus does not currently pay dividends.
What is BNB Plus’s EPS estimate?
BNB Plus’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does BNB Plus have?
BNB Plus has 7,197,228 shares outstanding.
What happened to BNB Plus’s price movement after its last earnings report?
BNB Plus reported an EPS of -$0.685 in its last earnings report, missing expectations of N/A. Following the earnings report the stock price went down -0.99%.
Which hedge fund is a major shareholder of BNB Plus?
Currently, no hedge funds are holding shares in BNBX
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
BNB Plus
BNB Plus Corp., established in 1983 and based in Stony Brook, NY, is a biotechnology firm dedicated to pioneering and commercializing technologies for the synthesis and identification of both deoxyribonucleic acid (DNA) and ribonucleic acid (RNA). The company's operations are divided into three distinct business segments. Its Therapeutic DNA Production Services division specializes in the enzymatic manufacturing of synthetic DNA, used in the creation of nucleic acid-based treatments, and also develops and markets its proprietary RNA Polymerase (RNAP) for mRNA therapeutic production. The MDx Testing Services segment concentrates on developing clinical molecular diagnostic and genetic assessments, in addition to providing comprehensive clinical laboratory testing services. Lastly, the DNA Tagging and Security Products and Services segment leverages DNA detection techniques for securing industrial supply chains and offering various security solutions.
Technical Analysis
ENDRA Life Sciences
―
Intelligent Bio Solutions
―
iSpecimen
―
BioNexus Gene Lab Corp
―
―
Ownership Overview
2.34% Insiders
0.42% Mutual Funds
<0.01% Other Institutional Investors
97.23% Public Companies and
Individual Investors
Options Prices
Currently, No data available
---